All In Biotech

Drug Trial Radar · NCT06546670

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

A Phase I/II Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

161

Planned (sponsor's estimate)

Start

Aug 15, 2024

Primary completion

May 1, 2028

Study completion May 27, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).

Conditions

  • Sickle Cell Disease

Interventions

  • ITU512Drug

    ITU512 is an investigational, oral, low molecular weight (LMW) compound.

  • PlaceboDrug

    An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEsTime frame: Up to approximately 60 days
  2. Part 1A, Part 1B , Part 1C: Dose discontinued due to AETime frame: Up to 30 days
  3. Part 2A, Part 2B: Incidence of AEs and SAEsTime frame: Up to 5 months
  4. Part 2A, Part 2B: Dose interruptions and reductionsTime frame: Up to 4 months
  5. Part 2A, Part 2B: Dose intensityTime frame: Up to 4 months
  6. Part 2B: Fetal hemoglobin (HbF)%Time frame: Month 4

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama · Recruiting

  • Quotient Sciences Sea View

    Miami, Florida · Completed

  • Boston Childrens Hospital

    Boston, Massachusetts · Recruiting

  • Icahn School Of Med At Mount Sinai

    New York, New York · Recruiting

  • Levine Cancer Insitute Carolinas Healthcare System

    Charlotte, North Carolina · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Childrens Hospital Of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Lifespan

    Providence, Rhode Island · Recruiting

  • UT Health Science Center

    Houston, Texas · Recruiting

  • Novartis Investigative Site

    São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Ankara, Sihhiye Altindag, Turkey (Türkiye) · Recruiting

  • Novartis Investigative Site

    Adana, Yuregir, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.